Between December 2020 and December 2022, China sold almost 1.6 billion Chinese-developed COVID-19 vaccines internationally. Countries in the Asia-Pacific region purchased almost one billion doses alone, while a significant number of doses were also exported to Latin America, Africa, and Eastern European countries. Chinese vaccines were made with conventional technology and were considered as a more cost-efficient solution to the general vaccine shortages in 2021.

In June 2022, the highest level of support for the use of COVID vaccine mandates for international travel was reported among people surveyed in India at **** percent. On the other hand, the lowest level of support for the use of such a mandate was reported in South Africa at **** percent. This statistic illustrates the level of support for using COVID vaccine mandate for international travel in 2022, by country.

Statistics from SPC's Public Health Division (PHD) on COVID-19 vaccination in Pacific Island Countries and Territories. Monitoring the impact of COVID-19 and the effectiveness of prevention and control strategies remains a public health priority. With the COVID-19 Public Health Emergency of International Concern declaration ending, some metrics have changed in frequency, source, or availability (i.e vaccination data). SPC will no longer continue to provide updated information on vaccination. The last update for this dataset was the 09 May 2023.

Find more Pacific data on PDH.stat.

Coronavirus Vaccine Market Outlook

The global market size for coronavirus vaccines was valued at around USD 45 billion in 2023, and it is expected to grow at a compound annual growth rate (CAGR) of 6.5% to reach approximately USD 79.8 billion by 2032. The primary growth factors driving this market include the ongoing need to manage COVID-19 outbreaks, the emergence of new virus variants, and the increasing global emphasis on pandemic preparedness and public health infrastructure enhancement.

One of the critical growth factors for the coronavirus vaccine market is the rising understanding of the long-term necessity for vaccination programs. Unlike initial assumptions that the pandemic could be quickly eradicated, it has become evident that COVID-19 may become endemic, requiring consistent and possibly seasonal vaccination efforts. This understanding has led both governments and private institutions to invest heavily in vaccine development, stockpiling, and distribution networks. Moreover, the introduction of booster doses to combat waning immunity has further solidified the market's growth trajectory.

Technological advancements in vaccine development have also played a significant role in the market's expansion. The rapid development and deployment of mRNA vaccines, such as those produced by Pfizer-BioNTech and Moderna, have set new benchmarks in the pharmaceutical industry. These innovations have not only increased the efficacy of vaccines but also reduced the time required for development and approval. This accelerated timeline is crucial for responding to new variants and potential future pandemics, driving further investments in cutting-edge vaccine technologies.

Regulatory support and international collaborations have also significantly influenced market growth. Governments worldwide have been proactive in approving emergency use authorizations and providing funding for vaccine research and development. Additionally, initiatives such as COVAX, led by the World Health Organization (WHO) and other global health organizations, aim to ensure equitable access to vaccines, particularly in low- and middle-income countries. These collaborative efforts are crucial for maintaining global health security and are anticipated to boost market demand.

From a regional perspective, North America and Europe have shown robust investments in vaccination programs and public health infrastructure, contributing to substantial market shares. However, the Asia Pacific region is expected to witness the highest growth rate, driven by large population bases, increasing healthcare spending, and concerted efforts to enhance vaccination coverage. Latin America and the Middle East & Africa are also emerging markets, with growing awareness and governmental initiatives to improve vaccine access and distribution.

Vaccine Type Analysis

The coronavirus vaccine market is segmented by vaccine type into mRNA vaccines, vector vaccines, protein subunit vaccines, inactivated vaccines, and others. Each of these types offers unique benefits and challenges, contributing to the overall diversity and resilience of the vaccine portfolio. mRNA vaccines, such as those developed by Pfizer-BioNTech and Moderna, have revolutionized the market with their high efficacy rates, rapid development cycles, and adaptability to new variants. These vaccines are set to dominate the market due to their technological superiority and strong clinical outcomes.

Vector vaccines, which use a modified virus to deliver genetic material into cells, represent another significant segment. Vaccines like the AstraZeneca-Oxford and Johnson & Johnson's Janssen fall into this category. These vaccines have shown efficacy in preventing severe disease and are easier to store and transport compared to mRNA vaccines. Their relatively lower production costs make them a viable option for mass immunization programs, especially in developing countries.

Protein subunit vaccines, which use harmless pieces of the virus to stimulate an immune response, are also gaining traction. Novavax is a key player in this segment, with its vaccine demonstrating strong efficacy and safety profiles. These vaccines are particularly appealing for individuals who may have allergic reactions to mRNA vaccines, offering an alternative that still provides robust protection. The scalability and stability of protein subunit vaccines make them an important component of the global vaccination strategy.

Inactivated vaccines, which use killed versions of the virus, have been

BackgroundThe present study aimed to investigate the prevalence of COVID-19 vaccine uptake among foreign migrants in China and to explore the determinants of their vaccine uptake behavior.MethodsFrom June to October 2021, we used convenience and snowball sampling to recruit a sample of 764 participants from five cities in which the overwhelming majority of foreign migrants in China live. The chi-square (χ2) tests were used to examine vaccination distribution according to demographic characteristics. Multivariate logistic regression models visualized by forest plot were used to investigate the associations between significant determinants and vaccine uptake.ResultsOverall, the prevalence of vaccination rate was 72.9% [95% confidence interval (CI): 69.9–76.0%]. Migrants whose social participation was very active [adjusted odds ratio (AOR): 2.95, 95% CI: 1.36–6.50, P = 0.007] or had perceived COVID-19 progression prevention by the vaccine (AOR: 1.74, 95% CI: 1.01–3.02, P = 0.012) had higher odds of vaccination compared to those whose social participation was inactive or who did not have this perception. Migrants who perceived the vaccine uptake process as complex (AOR: 0.47, 95% CI: 0.27–0.80, P = 0.016) or were unsure of their physical suitability for the vaccine (AOR: 0.40, 95% CI: 0.24–0.68, P < 0.001) had lower odds of vaccination compared to those who did not have these perceptions. Furthermore, migrants from emerging and developing Asian countries (AOR: 2.32, 95% CI: 1.07–5.21, P = 0.04) and the Middle East and Central Asia (AOR: 2.19, 95% CI: 1.07–4.50, P = 0.03) had higher odds of vaccination than those from major advanced economies (G7) countries, while migrants from other advanced economic countries (OR: 0.27, 95% CI: 0.11–0.63, P = 0.003) had lower odds of vaccination than those from G7 countries.ConclusionIt may be beneficial to promote vaccine uptake among migrants by ensuring effective community engagement, simplifying the appointment and uptake process, and advocating the benefits and target populations of the COVID-19 vaccine.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

About this Dataset

The data contains the following information:

Country- this is the country for which the vaccination information is provided; Country ISO Code - ISO code for the country; Date - date for the data entry; for some of the dates we have only the daily vaccinations, for others, only the (cumulative) total; Total number of vaccinations - this is the absolute number of total immunizations in the country; Total number of people vaccinated - a person, depending on the immunization scheme, will receive one or more (typically 2) vaccines; at a certain moment, the number of vaccination might be larger than the number of people; Total number of people fully vaccinated - this is the number of people that received the entire set of immunization according to the immunization scheme (typically 2); at a certain moment in time, there might be a certain number of people that received one vaccine and another number (smaller) of people that received all vaccines in the scheme; Daily vaccinations (raw) - for a certain data entry, the number of vaccination for that date/country; Daily vaccinations - for a certain data entry, the number of vaccination for that date/country; Total vaccinations per hundred - ratio (in percent) between vaccination number and total population up to the date in the country; Total number of people vaccinated per hundred - ratio (in percent) between population immunized and total population up to the date in the country; Total number of people fully vaccinated per hundred - ratio (in percent) between population fully immunized and total population up to the date in the country; Number of vaccinations per day - number of daily vaccination for that day and country; Daily vaccinations per million - ratio (in ppm) between vaccination number and total population for the current date in the country; Vaccines used in the country - total number of vaccines used in the country (up to date); Source name - source of the information (national authority, international organization, local organization etc.); Source website - website of the source of information;

Tasks: Track the progress of COVID-19 vaccination What vaccines are used and in which countries? What country is vaccinated more people? What country is vaccinated a larger percent from its population?

This data is valuble in relation to the health, financial, and engineering sectors.

Category

Health & Medicine

Keywords

Health,Medicine,covid-19,dataset,progress

Row Count

5824

Price

$120.00

Abstract Health diplomacy has played a vital role worldwide during the coronavirus outbreak. One crucial mechanism in this regard has been “vaccine diplomacy,” which describes country efforts to share COVID-19 vaccines. China and India are ahead of other countries in bilateral vaccine donations due to their South-South Cooperation policies. Looking forward, how and why are these two countries employing their vaccine diplomacy strategies? We compare the engagement of both in this field using a Comparative Foreign Policy Analysis framework. Our results suggest that neither is acting only for altruistic reasons, because economic and political interests are the main drivers behind their strategies.

Disclaimer: As of January 2025, SPC will no longer provide updated information on COVID-19 cases and deaths. The information presented on this page is for reference only. For current epidemic and emerging disease alerts in the Pacific region, please visit: https://www.spc.int/epidemics/

Statistics from SPC's Public Health Division (PHD) on COVID-19 vaccination in Pacific Island Countries and Territories. Monitoring the impact of COVID-19 and the effectiveness of prevention and control strategies remains a public health priority. With the COVID-19 Public Health Emergency of International Concern declaration ending, some metrics have changed in frequency, source, or availability (i.e vaccination data). SPC will no longer continue to provide updated information on vaccination. The last update for this dataset was the 09 May 2023.

Find more Pacific data on PDH.stat.

The Our World in Data COVID vaccination data

To bring this pandemic to an end, a large share of the world needs to be immune to the virus. The safest way to achieve this is with a vaccine. Vaccines are a technology that humanity has often relied on in the past to bring down the death toll of infectious diseases.

Within less than 12 months after the beginning of the COVID-19 pandemic, several research teams rose to the challenge and developed vaccines that protect from SARS-CoV-2, the virus that causes COVID-19.

Now the challenge is to make these vaccines available to people around the world. It will be key that people in all countries — not just in rich countries — receive the required protection. To track this effort we at Our World in Data are building the international COVID-19 vaccination dataset that we make available on this page.

COVID-19 Vaccine Market Outlook

According to our latest research, the global COVID-19 vaccine market size in 2024 stands at USD 41.2 billion, reflecting the ongoing demand for both primary vaccination and booster doses amid evolving virus strains and public health strategies. The market is projected to reach USD 56.8 billion by 2033, growing at a CAGR of 3.6% during the forecast period. This steady growth is primarily driven by the continuous emergence of new SARS-CoV-2 variants, expanded immunization programs, and the integration of COVID-19 vaccines into routine immunization schedules globally.

The COVID-19 vaccine market is experiencing robust growth due to several key factors. First, the persistent threat of new virus variants, such as Omicron sub-lineages, has necessitated ongoing vaccine updates and booster campaigns. Governments and health organizations globally are prioritizing the procurement and distribution of updated vaccines to mitigate the risk of severe illness, hospitalization, and mortality. Additionally, the expansion of vaccination eligibility to include younger age groups and vulnerable populations has broadened the addressable market. These factors, coupled with the increasing adoption of annual or biannual booster programs, are fueling sustained demand for COVID-19 vaccines across both developed and developing regions.

Another significant driver is the continued investment in research and development by both public and private sectors. Pharmaceutical companies are leveraging advanced technologies, such as mRNA platforms, to accelerate the development of next-generation vaccines with improved efficacy, broader variant coverage, and enhanced safety profiles. The rapid regulatory approvals and emergency use authorizations for updated vaccines have further streamlined market entry and ensured timely availability. Moreover, the integration of COVID-19 vaccines into national immunization schedules is anticipated to provide a stable and recurring revenue stream for manufacturers, reinforcing the market's long-term growth prospects.

The market is also benefiting from heightened public awareness and proactive government initiatives. Many countries have implemented robust vaccination campaigns, supported by extensive funding, public-private partnerships, and international collaborations. Initiatives such as COVAX have played a crucial role in ensuring equitable vaccine access for low- and middle-income countries, thereby expanding the global market footprint. Furthermore, the increasing role of pharmacies, clinics, and non-traditional healthcare settings in vaccine administration has improved accessibility and convenience for the general population, driving higher vaccination rates.

From a regional perspective, North America and Europe continue to dominate the COVID-19 vaccine market due to high vaccination coverage, advanced healthcare infrastructure, and strong government support. However, the Asia Pacific region is emerging as a key growth area, driven by large population bases, rising healthcare investments, and expanding immunization programs. Latin America and the Middle East & Africa are also witnessing increased market activity, supported by international aid and local manufacturing initiatives. These regional dynamics underscore the market's global reach and the importance of tailored strategies to address diverse healthcare needs and infrastructure capabilities.

Vaccine Type Analysis

The COVID-19 vaccine market is segmented by vaccine type into mRNA vaccines, vector vaccines, protein subunit vaccines, inactivated vaccines, and others. Among these, mRNA vaccines have established a dominant position due to their high efficacy, rapid development timelines, and adaptability to emerging variants. The success of Pfizer-BioNTech and Moderna vaccines has set a new benchmark in vaccine technology, prompting further investments in mRNA platforms. These vaccines offer the advantage of quick reconfi

Approved COVID-19 Vaccines Market Outlook

The global market size for approved COVID-19 vaccines stood at approximately USD 45 billion in 2023 and is projected to reach around USD 78 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.5% during the forecast period. This substantial growth is primarily driven by continuous advancements in vaccine technology, increasing global vaccination drives, and the emergence of new variants necessitating booster doses.

One of the primary growth factors for the approved COVID-19 vaccines market is the ongoing need for booster vaccinations. As new variants of the virus emerge, vaccine manufacturers are continuously enhancing existing vaccines to tackle these variants effectively. This continuous innovation ensures sustained demand for updated vaccines, thereby propelling market growth. Additionally, governments worldwide are investing heavily in vaccination programs to achieve herd immunity, further boosting market size. Initiatives like COVAX, which aim to provide equitable vaccine access, are also significant contributors to market expansion.

Another crucial factor driving market growth is the increased awareness and acceptance of vaccines among the global population. Intensive public health campaigns and educational movements have led to a higher acceptance rate of vaccines, reducing vaccine hesitancy. This trend is particularly significant in emerging economies where initial vaccine skepticism was high. The successful roll-out of initial vaccine doses has built public confidence, thereby increasing the uptake of booster doses and new vaccine variants.

The collaboration between pharmaceutical companies and governments has also played a pivotal role in the growth of the COVID-19 vaccines market. Strategic partnerships for vaccine production, distribution, and administration have streamlined the supply chain, making vaccines more accessible to the public. These collaborations have also facilitated bulk purchasing agreements, which have provided cost advantages and enhanced market penetration across various regions. Moreover, the establishment of new manufacturing facilities and the expansion of existing ones have significantly accelerated vaccine production capabilities.

The development of the COVID-19 RNA Vaccine has been a groundbreaking advancement in the fight against the pandemic. Unlike traditional vaccines, RNA vaccines work by introducing a small piece of genetic material from the virus into the body, prompting an immune response without using a live virus. This innovative approach has allowed for rapid development and deployment, significantly contributing to the global vaccination efforts. The flexibility of RNA technology also enables quick updates to the vaccine to address new variants, ensuring continued protection as the virus evolves. This adaptability has made RNA vaccines a crucial tool in achieving widespread immunity and controlling the spread of COVID-19.

Regionally, North America leads the market due to its advanced healthcare infrastructure and early adoption of vaccination programs. Europe follows closely, with significant contributions from countries like Germany, France, and the UK. The Asia Pacific region is witnessing rapid growth, driven by substantial investments in healthcare infrastructure and large-scale vaccination drives in countries like India and China. Meanwhile, Latin America and the Middle East & Africa are gradually catching up, supported by international aid and improving healthcare systems. The regional diversity ensures a balanced growth outlook for the global market.

Vaccine Type Analysis

The market for approved COVID-19 vaccines is segmented into various types, including mRNA vaccines, vector vaccines, protein subunit vaccines, inactivated vaccines, and others. mRNA vaccines, such as those developed by Pfizer-BioNTech and Moderna, have gained significant traction due to their high efficacy rates and the rapid speed of development. The flexibility of mRNA technology to adapt swiftly to new variants has positioned them as a frontrunner in the market. This segment is expected to continue its dominance, supported by ongoing research and development activities aimed at enhancing vaccine formulations and delivery mechanisms.

Vector vaccines, which use a modified virus to deliver genetic material into cells, represent another significant segment. AstraZeneca and Johnson & Johnson are key players in t

Vaccine Strategy The vaccine strategy must meet three public health objectives: — Reducing mortality and serious forms of disease — Protecting caregivers and the care system — Ensuring the safety of vaccines and vaccinations As part of this strategy, places dedicated to vaccination are set up. ### Data The dataset contains a list of places dedicated to COVID-19 vaccination. This list comes from the declarations of the Regional Health Agencies, which consolidate the centres of their regions. The data is extracted every hour. There is not always an update or a fix, only the latest version is available. A new field is added today (centre_type). He comes to tag the center as “Great Center”, “Civil Security”, “USMP”, “USHI”, “USHA”, “Mobile Team”, “SSA”. Attention, in reuses, centres whose field “centre_close” = t (true) are not intended to be exploded to the public. These are centres for specific audiences such as prisons that are present in the list of vaccination centres, but not exposed on www.sante.fr 25/06/21 — A list of fictional vaccination centres has been added (1 per foreign country). They represent all vaccination centres in a country. They are not exposed to the public via sante.fr, it is, of course, not possible to take rdv. The source of the list is that of the Ministry of Foreign Affairs available on data.gouv.fr They have no geographical positions (position 0 0). Their only usefulness is internal to the vaccination data capture system. The GID of these centers is 9 characters and starts with 9900xxxxx

COVID-19 Vaccines-Production Capacity & Development Timeline Market Outlook

According to our latest research, the global COVID-19 vaccines market size reached USD 40.2 billion in 2024, reflecting a significant contraction from the pandemic’s peak but remaining a critical segment of the global biopharmaceutical industry. The market is projected to grow at a CAGR of 3.7% from 2025 to 2033, reaching a forecasted value of USD 56.7 billion by 2033. This growth is primarily driven by the ongoing need for booster vaccinations, the emergence of new viral variants, and sustained investments in vaccine research and production capabilities worldwide. The market’s resilience is further supported by government procurement programs and the expansion of vaccine access in emerging economies.

The evolution of the COVID-19 vaccines market is shaped by several growth factors, notably the persistent circulation of SARS-CoV-2 and the continuous emergence of new variants that challenge existing immunity levels. Governments and health organizations worldwide remain vigilant, prioritizing the development and distribution of updated vaccines to counter variant-driven outbreaks. The introduction of bivalent and multivalent vaccines, designed to offer protection against multiple strains, has spurred ongoing demand. Furthermore, the increasing reliance on annual or biannual booster doses for vulnerable populations, such as the elderly and immunocompromised individuals, ensures a steady baseline for vaccine consumption. The integration of COVID-19 vaccination into routine immunization schedules is also anticipated to contribute to market stability over the forecast period.

Another key driver is the remarkable progress in vaccine technology, particularly the rapid advancement and deployment of mRNA vaccine platforms. The success of mRNA vaccines has not only revolutionized the response to COVID-19 but has also accelerated research and development for other infectious diseases. This technological leap has encouraged investments in flexible manufacturing infrastructure, enabling faster adaptation to emerging threats and enhancing global production capacity. Additionally, partnerships between pharmaceutical companies, governments, and contract manufacturing organizations (CMOs) have optimized supply chains, improved scalability, and facilitated technology transfer to developing regions. These collaborative efforts are essential for maintaining readiness against future pandemics and for addressing ongoing global health challenges.

Market growth is further bolstered by proactive government policies and international collaborations aimed at ensuring equitable vaccine distribution. Initiatives such as COVAX and bilateral agreements have played a crucial role in expanding vaccine access to low- and middle-income countries, thereby stimulating demand and supporting market expansion. The increasing participation of private procurement channels, including hospitals, clinics, and pharmacies, has diversified distribution networks and improved accessibility for broader populations. Moreover, the push for localized manufacturing and regulatory harmonization is streamlining vaccine approval processes and reducing dependency on a limited number of global suppliers. These trends collectively underpin the sustained growth trajectory of the COVID-19 vaccines market.

Regionally, North America and Europe continue to dominate the COVID-19 vaccines market, accounting for the largest shares due to robust healthcare infrastructure, high vaccination rates, and substantial government funding. However, the Asia Pacific region is exhibiting the fastest growth, driven by large-scale immunization campaigns, expanding manufacturing capabilities, and rising awareness about the importance of vaccination. Countries such as China and India are emerging as significant players in both vaccine production and consumption, supported by favorable policy frameworks and increasing investments in biotechnology. Latin America and the Middle East & Africa are also witnessing gradual improvements in vaccine coverage, although challenges related to infrastructure and affordability persist. Overall, the regional dynamics are expected to evolve as global efforts intensify to achieve comprehensive vaccine coverage and pandemic preparedness.

COVID-19 RNA Vaccine Market Outlook

The global COVID-19 RNA Vaccine market size was valued at approximately USD 25 billion in 2023, and it is projected to reach USD 80 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 14% during the forecast period. The significant growth factor driving this market is the unprecedented urgency and global demand for effective immunization solutions to combat the COVID-19 pandemic. The rapid development, approval, and distribution of RNA vaccines such as mRNA-1273 and BNT162b2 have revolutionized the vaccine industry, providing a novel mechanism that utilizes messenger RNA to instruct cells to produce viral proteins, thereby triggering an immune response.

The primary growth factor for the COVID-19 RNA vaccine market is the efficacy and speed of RNA vaccine development. Traditional vaccine development can take years, whereas RNA vaccines can be developed and scaled up quickly due to their synthetic nature and the simplicity of their manufacturing processes. This rapid development capability has been crucial in addressing the urgent need for COVID-19 vaccines. Additionally, RNA vaccines have exhibited high efficacy rates in clinical trials, further bolstering public confidence and demand. Innovations in RNA technology are also paving the way for improvements in storage and distribution, making these vaccines more accessible globally.

Another significant growth driver is the ongoing threat of new COVID-19 variants. As the virus mutates, the need for adaptable and quickly producible vaccines becomes more pressing. RNA vaccines offer a flexible platform that can be rapidly modified to target new viral strains. This adaptability ensures continued relevance and demand for RNA vaccines in the long term, as booster shots and updated vaccines become necessary to maintain immunity against evolving virus strains. Furthermore, global vaccination campaigns and government initiatives to secure vaccine supplies are playing a pivotal role in market growth.

The scalability of RNA vaccine production is a key factor contributing to market growth. Unlike traditional vaccines that require cell cultures or animal products, RNA vaccines can be synthesized in large quantities using relatively simple and scalable biochemical processes. This ease of production not only accelerates the manufacturing timeline but also allows for cost-effective mass production. The increased production capacity has enabled manufacturers to meet the global demand more efficiently, ensuring widespread distribution and administration of vaccines.

The emergence of mRNA Vaccines & Therapeutics has been a pivotal development in the fight against COVID-19. These vaccines, which utilize messenger RNA to instruct cells to produce viral proteins, have not only proven effective against the original strain of the virus but also offer a flexible platform for rapid adaptation to new variants. This adaptability is crucial as the virus continues to evolve, presenting new challenges in maintaining public health. The success of mRNA vaccines has sparked a broader interest in their potential applications beyond infectious diseases, exploring possibilities in cancer treatment and other therapeutic areas. This innovation marks a significant shift in vaccine technology, promising a new era of medical advancements.

The regional outlook for the COVID-19 RNA vaccine market indicates robust growth across various geographies. North America, particularly the United States, has been a leading region in terms of vaccine development and distribution, supported by substantial government funding and advanced healthcare infrastructure. Europe follows closely, with significant contributions from countries like Germany and the UK. The Asia Pacific region is also witnessing remarkable growth, driven by initiatives in countries such as China and India to ramp up vaccine production and distribution. Latin America and the Middle East & Africa are gradually increasing their market shares through international collaborations and local manufacturing efforts.

Vaccine Type Analysis

The COVID-19 RNA vaccine market is segmented by vaccine type, with major categories including mRNA-1273, BNT162b2, CVnCoV, ARCoV, and others. mRNA-1273, developed by Moderna, has been a frontrunner in the race to vaccinate the global population. Its high efficacy rate, coupled with robust production capabilities, has made it a significant player in the market. Unlike traditional vaccines, mRNA-12

COVID-19 Stats & Trends

Context

This dataset seeks to provide insights into what has changed due to policies aimed at combating COVID-19 and evaluate the changes in community activities and its relation to reduced confirmed cases of COVID-19. The reports chart movement trends, compared to an expected baseline, over time (from 2020/02/15 to 2020/02/05) by geography (across 133 countries), as well as some other stats about the country that might help explain the evolution of the disease.

Content

1. Grocery & Pharmacy: Mobility trends for places like grocery markets, food warehouses, farmers' markets, specialty food shops, drug stores, and pharmacies.
2. Parks: Mobility trends for places like national parks, public beaches, marinas, dog parks, plazas, and public gardens.
3. Residential: Mobility trends for places of residence.
4. Retail & Recreation: Mobility trends for places like restaurants, cafes, shopping centers, theme parks, museums, libraries, and movie theaters.
5. Transit stations: Mobility trends for places like public transport hubs such as subway, bus, and train stations.
6. Workplaces: Mobility trends for places of work.
7. Total Cases: Total number of people infected with the SARS-CoV-2.
8. Fatalities: Total number of deaths caused by CoV-19.
9. Government Response Stringency Index: Additive score of nine indicators of government response to CoV-19: School closures, workplace closures, cancellation of public events, public information campaigns, stay at home policies, restrictions on internal movement, international travel controls, testing policy, and contact tracing.
10. COVID-19 Testing: Total number of tests performed.
11. Total Vaccinations: Total number of shots given.
12. Total People Vaccinated: Total number of people given a shot.
13. Total People Fully Vaccinated: Total number of people fully vaccinated (might require two shots of some vaccines).
14. Population: Total number of inhabitants.
15. Population Density per km2: Number of human inhabitants per square kilometer.
16. Health System Index: Overall performance of the health system.
17. Human Development Index (HDI): Summary index based on life expectancy at birth, expected years of schooling for children and mean years of schooling for adults, and GNI per capita.
18. GDP (PPP) per capita: Gross Domestic Product (GDP) per capita based on Purchasing Power Parity (PPP), taking into account the relative cost of local goods, services and inflation rates of the country, rather than using international market exchange rates, which may distort the real differences in per capita income.
19. Elderly Population (percentage): Percentage of the population above the age of 65 years old.

References & Acknowledgements

Bing COVID-19 data. Available at: https://github.com/microsoft/Bing-COVID-19-Data COVID-19 Community Mobility Report. Available at: https://www.google.com/covid19/mobility/ COVID-19: Government Response Stringency Index. Available at: https://ourworldindata.org/grapher/covid-stringency-index Coronavirus (COVID-19) Testing. Available at: https://github.com/owid/covid-19-data/blob/master/public/data/testing/covid-testing-all-observations.csv Coronavirus (COVID-19) Vaccination. Available at: https://raw.githubusercontent.com/owid/covid-19-data/master/public/data/vaccinations/vaccinations.csv List of countries and dependencies by population. Available at: https://www.kaggle.com/tanuprabhu/population-by-country-2020 List of countries and dependencies by population density. Available at: https://www.kaggle.com/tanuprabhu/population-by-country-2020 List of countries by Human Development Index. Available at: http://hdr.undp.org/en/data Measuring Overall Health System Performance. Available at: https://www.who.int/healthinfo/paper30.pdf?ua=1 List of countries by GDP (PPP) per capita. Available at: https://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD List of countries by age structure (65+). Available at: https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS

Authors

• Diogo Silva, up201706892@fe.up.pt

This publication corresponds to the Common Data Model (CDM) specification of the Baseline Use Case proposed in T.5.2 (WP5) in the BY-COVID project on “SARS-CoV-2 Vaccine(s) effectiveness in preventing SARS-CoV-2 infection.” Research Question: “How effective have the SARS-CoV-2 vaccination programmes been in preventing SARS-CoV-2 infections?” Intervention (exposure): COVID-19 vaccine(s) Outcome: SARS-CoV-2 infection Subgroup analysis: Vaccination schedule (type of vaccine) Study Design: An observational retrospective longitudinal study to assess the effectiveness of the SARS-CoV-2 vaccine in preventing SARS-CoV-2 infections using routinely collected social, health and care data from several countries. A causal model was established using Directed Acyclic Graphs (DAGs) to map domain knowledge, theories and assumptions about the causal relationship between exposure and outcome. The DAG developed for the research question of interest is shown below. Cohort definition: All people eligible to be vaccinated (from 5 to 115 years old, included) or with, at least, one dose of a SARS-CoV-2 vaccine (any of the available brands) having or not a previous SARS-CoV-2 infection. Inclusion criteria: All people vaccinated with at least one dose of the COVID-19 vaccine (any available brands) in an area of residence. Any person eligible to be vaccinated (from 5 to 115 years old, included) with a positive diagnosis (irrespective of the type of test) for SARS-CoV-2 infection (COVID-19) during the period of study. Exclusion criteria: People not eligible for the vaccine (from 0 to 4 years old, included) Study period: From the date of the first documented SARS-CoV-2 infection in each country to the most recent date in which data is available at the time of analysis. Roughly from 01-03-2020 to 30-06-2022, depending on the country. Files included in this publication: Causal model (responding to the research question) SARS-CoV-2 vaccine effectiveness causal model v.1.0.0 (HTML) - Interactive report showcasing the structural causal model (DAG) to answer the research question SARS-CoV-2 vaccine effectiveness causal model v.1.0.0 (QMD) - Quarto RMarkdown script to produce the structural causal model Common data model specification (following the causal model) SARS-CoV-2 vaccine effectiveness data model specification (XLXS) - Human-readable version (Excel) SARS-CoV-2 vaccine effectiveness data model specification dataspice (HTML) - Human-readable version (interactive report) SARS-CoV-2 vaccine effectiveness data model specification dataspice (JSON) - Machine-readable version Synthetic dataset (complying with the common data model specifications) SARS-CoV-2 vaccine effectiveness synthetic dataset (CSV) [UTF-8, pipe | separated, N~650,000 registries] SARS-CoV-2 vaccine effectiveness synthetic dataset EDA (HTML) - Interactive report of the exploratory data analysis (EDA) of the synthetic dataset SARS-CoV-2 vaccine effectiveness synthetic dataset EDA (JSON) - Machine-readable version of the exploratory data analysis (EDA) of the synthetic dataset SARS-CoV-2 vaccine effectiveness synthetic dataset generation script (IPYNB) - Jupyter notebook with Python scripting and commenting to generate the synthetic dataset #### Baseline Use Case: SARS-CoV-2 vaccine effectiveness assessment - Common Data Model Specification v.1.1.0 change log #### Updated Causal model to eliminate the consideration of 'vaccination_schedule_cd' as a mediator Adjusted the study period to be consistent with the Study Protocol Updated 'sex_cd' as a required variable Added 'chronic_liver_disease_bl' as a comorbidity at the individual level Updated 'socecon_lvl_cd' at the area level as a recommended variable Added crosswalks for the definition of 'chronic_liver_disease_bl' in a separate sheet Updated the 'vaccination_schedule_cd' reference to the 'Vaccine' node in the updated DAG Updated the description of the 'confirmed_case_dt' and 'previous_infection_dt' variables to clarify the definition and the need for a single registry per person The scripts (software) accompanying the data model specification are offered "as-is" without warranty and disclaiming liability for damages resulting from using it. The software is released under the CC-BY-4.0 licence, which permits you to use the content for almost any purpose (but does not grant you any trademark permissions), so long as you note the license and give credit.

This study provides a macro-level societal and health system focused analysis of child vaccination rates in 30 European countries, exploring the effect of context on coverage. The importance of demography and health system attributes on health care delivery are recognized in other fields, but generally overlooked in vaccination. The analysis is based on correlating systematic data built up by the Models of Child Health Appraised (MOCHA) Project with data from international sources, so as to exploit a one-off opportunity to set the analysis within an overall integrated study of primary care services for children, and the learning opportunities of the ‘natural European laboratory’. The descriptive analysis shows an overall persistent variation of coverage across vaccines with no specific vaccination having a low rate in all the EU and EEA countries. However, contrasting with this, variation between total uptake per vaccine across Europe suggests that the challenge of low rates is related to country contexts of either policy, delivery, or public perceptions. Econometric analysis aiming to explore whether some population, policy and/or health system characteristics may influence vaccination uptake provides important results - GDP per capita and the level of the population’s higher education engagement are positively linked with higher vaccination coverage, whereas mandatory vaccination policy is related to lower uptake rates. The health system characteristics that have a significant positive effect are a cohesive management structure; a high nurse/doctor ratio; and use of practical care delivery reinforcements such as the home-based record and the presence of child components of e‑health strategies.

Estimates of vaccine sentiment for ITL1 geographies (countries and regions of the UK) split by characteristics including age, employment, tenure, health and Index of Multiple Deprivation. Analysis based on the Opinions and Lifestyle Survey (OPN).

Between December 2020 and December 2022, China delivered more than 1.4 billion COVID-19 vaccines to other countries. The Asia-Pacific region received about two-thirds of all deliveries, while most European countries did not import any Chinese-made COVID-19 vaccines. The export channels include both sales and donations.